Press Conference at EHA 2012:

The Phase 2 dose-ranging study MT103-206 evaluated the efficacy, safety and tolerability of blinatumomab in adult patients with B-precursor Acute Lymphoblastic Leukaemia (ALL) who had relapsed following treatment with standard front-line chemotherapy or allogeneic stem cell transplant.

Patients received blinatumomab for 28 days followed by two weeks off therapy over a six week treatment cycle, for up to five treatment cycles. Patients received a continuous intravenous infusion of blinatumomab at an initial dose of five or 15 micrograms/m2 per day, escalating to 30 micrograms for the remainder of the treatment. The primary endpoint of the study was the rate of complete remission (CR) and complete remission with partial hematologic recovery (CRh*). Secondary endpoints included molecular response rate, duration of response and overall survival. All 36 patients were evaluable for efficacy and safety.

Filming supported by Amgen